Market Overview:
The global ovarian cancer market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of ovarian cancer, increasing awareness about ovarian cancer, and technological advancements in the field of diagnosis and treatment of ovarian cancer. However, the high cost associated with diagnosis and treatment of ovarian cancer is likely to restrain the growth of this market during the forecast period. Based on type, the global ovarian cancer market can be segmented into surgery, chemotherapy, radiation therapy, and biological therapy. Surgery is currently considered as a standard treatment for early-stage ovarian cancers; however, chemotherapy has emerged as an alternative for patients with advanced-stage disease. Radiation therapy is used primarily in combination with surgery or chemotherapy for treating recurrent or metastatic tumors.
Product Definition:
Ovarian cancer is a type of cancer that forms in the ovaries. It is the fifth most common cause of cancer death among women.
Surgery:
Ovarian cancer is a disease of the female reproductive system. It is one of the most common gynecologic malignancies and its incidence has been increasing over the last decades.
Chemotherapy:
Chemotherapy is the use of drugs or chemical substances to treat cancer. Chemotherapy used in ovarian cancer may be given by vein, oral medication or injection. Ovarian cancer that has spread to other organs may also be treated with chemotherapy. The type of chemotherapy depends on the stage and grade of the patient’s disease, which can range from simple monitoring therapy to intensive treatment depending upon factors such as age, health status and tumor characteristics.
Application Insights:
The others application segment held the largest share of more than 70.0% in 2017. This is due to the increasing incidence rate of other cancers among women, such as breast cancer and prostate cancer. According to a research study published by NCBI in 2018, it was found that around 1 out of every 4 men above 60 years have some form of prostate cancer or benign prostatic hyperplasia (BPH). Similarly, around 1 out of every 8 women above 60 years has some form of breast tumor or carcinoma in situ (CIS). Thus, growing prevalence rates for these two common cancers among older population groups are expected to contribute towards growth during forecast period.
However, hospitals application segment is expected to witness lucrative CAGR during forecast period owing to rising number ovulation induction drugs approved by FDA since past few years which are used for ovarian stimulation prior with IVF procedures and hence driving market growth since past few years.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to high healthcare expenditure, favorable reimbursement policies, and increasing awareness about early diagnosis. In addition, a higher number of clinical trials for ovarian cancer is also expected to fuel the growth during the forecast period. Asia Pacific is estimated to witness lucrative growth over the next eight years owing to improving healthcare infrastructure and rising disposable income levels in emerging countries such as China and India.
AbbVie Inc., FUJIFILM Diosynth Biotechnologies U.S., Merck & Co., Celgene Corporation; AbbVie Inc.; FUJIFILM Diosynth Biotechnologies U S A; Merck & Co.
Growth Factors:
- Increasing incidence of ovarian cancer
- Growing awareness about ovarian cancer and its symptoms
- Rising demand for early diagnosis and treatment of ovarian cancer
- Technological advancements in the field of ovarian cancer diagnosis and treatment
- Availability of government funding for research on ovarian cancer
Scope Of The Report
Report Attributes
Report Details
Report Title
Ovarian Cancer Market Research Report
By Type
Surgery, Chemotherapy, Radiation, Biological Therapy
By Application
Hospitals, Clinics, Others
By Companies
Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Novogen, Genentech, Aetera Zenteris, Boehringer Ingelheim, Roche
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
241
Number of Tables & Figures
169
Customization Available
Yes, the report can be customized as per your need.
Global Ovarian Cancer Market Report Segments:
The global Ovarian Cancer market is segmented on the basis of:
Types
Surgery, Chemotherapy, Radiation, Biological Therapy
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol Myers Squibb
- Eli Lilly
- GlaxoSmithKline
- Janssen Pharmaceuticals
- Novogen
- Genentech
- Aetera Zenteris
- Boehringer Ingelheim
- Roche
Highlights of The Ovarian Cancer Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Surgery
- Chemotherapy
- Radiation
- Biological Therapy
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ovarian Cancer Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ovarian cancer is a type of cancer that starts in the ovaries. Ovarian cancer can occur in either the female reproductive system (the uterus, fallopian tubes, and ovaries) or the male reproductive system (the testicles). Ovarian cancer is one of the most common cancers in women and one of the deadliest. In 2016, ovarian cancer caused about 27,000 deaths worldwide.
Some of the major players in the ovarian cancer market are Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceuticals, Novogen, Genentech, Aetera Zenteris, Boehringer Ingelheim, Roche.
The ovarian cancer market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ovarian Cancer Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ovarian Cancer Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ovarian Cancer Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ovarian Cancer Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ovarian Cancer Market Size & Forecast, 2020-2028
4.5.1 Ovarian Cancer Market Size and Y-o-Y Growth
4.5.2 Ovarian Cancer Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Surgery
5.2.2 Chemotherapy
5.2.3 Radiation
5.2.4 Biological Therapy
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ovarian Cancer Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ovarian Cancer Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Surgery
9.6.2 Chemotherapy
9.6.3 Radiation
9.6.4 Biological Therapy
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Surgery
10.6.2 Chemotherapy
10.6.3 Radiation
10.6.4 Biological Therapy
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Surgery
11.6.2 Chemotherapy
11.6.3 Radiation
11.6.4 Biological Therapy
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Surgery
12.6.2 Chemotherapy
12.6.3 Radiation
12.6.4 Biological Therapy
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Surgery
13.6.2 Chemotherapy
13.6.3 Radiation
13.6.4 Biological Therapy
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ovarian Cancer Market: Competitive Dashboard
14.2 Global Ovarian Cancer Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bristol Myers Squibb
14.3.2 Eli Lilly
14.3.3 GlaxoSmithKline
14.3.4 Janssen Pharmaceuticals
14.3.5 Novogen
14.3.6 Genentech
14.3.7 Aetera Zenteris
14.3.8 Boehringer Ingelheim
14.3.9 Roche
